Somatropin (HGH) vs Pancragen
Side-by-side comparison of key properties, dosing, and research.
Growth Hormone PeptidesAnti-Aging & Longevity
Somatropin (HGH)Anti-Aging & Longevity
Pancragen- Summary
- Somatropin is recombinant human growth hormone (rhGH), identical in structure to the 191-amino acid pituitary-derived growth hormone. It is FDA-approved for growth hormone deficiency, short stature, and wasting conditions. Off-label, it is widely explored for body composition, anti-aging, and performance enhancement, though significant risks accompany unsupervised use.
- Pancragen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the pancreas. It supports the function of both exocrine and endocrine pancreatic cells, promotes normalization of insulin secretion from beta cells, and may offer protective effects against pancreatic aging and diabetic progression.
- Half-Life
- 2-3 hours (subcutaneous); 20-30 minutes (intravenous)
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- Subcutaneous, Intramuscular (less common)
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 0.15-0.3 mg/day (adults); titrated to IGF-1 levels
- 10 mg per day
- Frequency
- Once daily
- Daily for 10–30 days
- Key Benefits
- Increases lean muscle mass and reduces body fat (particularly visceral)
- Restores growth hormone deficiency (FDA-approved)
- Improves bone mineral density
- Enhances exercise capacity and recovery
- Supports skin thickness and collagen synthesis
- Improves lipid profile in GHD patients
- Explored for anti-aging and cellular regeneration
- Supports pancreatic beta cell function and insulin secretion
- May improve glucose metabolism in early metabolic dysfunction
- Protective effects on exocrine pancreatic tissue
- Anti-aging effects on pancreatic cells
- Potential support in type 2 diabetes management alongside standard care
- Reduces pancreatic cellular apoptosis from metabolic stress
- Complementary to GLP-1 agonists in metabolic protocols
- Side Effects
- Fluid retention and edema (common, dose-dependent)
- Carpal tunnel syndrome
- Joint and muscle pain
- Insulin resistance and elevated blood glucose
- +3 more
- Generally well tolerated
- Mild injection site reactions
- No significant hypoglycemic events reported at standard doses as monotherapy
- Stacks With
- —
- —